Immunome, Inc. is a clinical-stage targeted oncology company, which is focused on developing first-in-class and targeted therapies designed to improve outcomes for cancer patients. The Company is engaged in advancing an innovative portfolio of therapeutics in the design, development, and commercialization of targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Its advanced pipeline programs are varegacestat, a gamma secretase inhibitor which is in a Phase III trial for the treatment of desmoid tumors; IM-1021, an ROR1-targeted ADC which is in a Phase I trial, and IM-3050, a FAP-targeted radioligand. The Company's pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. IM-1617 is a potential first-in-class ADC that targets an undisclosed receptor that is expressed in a range of solid tumors, including colorectal cancer and ovarian cancers.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļIMNM
āļāļ·āđāļāļāļĢāļīāļĐāļąāļImmunome Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļOct 02, 2020
āļāļĩāļāļĩāđāļSiegall (Clay B)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ118
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļOct 02
āļāļĩāđāļāļĒāļđāđ18702 N. Creek Parkway
āđāļĄāļ·āļāļBOTHELL
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ98011
āđāļāļĢāļĻāļąāļāļāđ16103213700
āđāļ§āđāļāđāļāļāđhttps://immunome.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļIMNM
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļOct 02, 2020
āļāļĩāļāļĩāđāļSiegall (Clay B)
Dr. Clay B. Siegall, Ph.D.
Dr. Clay B. Siegall, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
Mr. Philip R. Wagenheim
Director
Mr. Kinney Horn
Chief Business Officer
Mr. Max Rosett
Chief Financial Officer
Mr. Isaac Barchas, J.D.
Lead Independent Director
Lead Independent Director
Dr. Robert (Bob) Lechleider, M.D.
Dr. Robert (Bob) Lechleider, M.D.
Chief Medical Officer
Dr. Jack Higgins, Ph.D.
Chief Scientific Officer
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Independent Director
Ms. Sandra G. Stoneman
Chief Legal Officer, General Counsel, Corporate Secretary
Chief Legal Officer, General Counsel, Corporate Secretary
Mr. James P. (Jim) Boylan
Mr. James P. (Jim) Boylan
Independent Director
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Dr. Clay B. Siegall, Ph.D.
Dr. Clay B. Siegall, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
Mr. Philip R. Wagenheim
Director
Mr. Kinney Horn
Chief Business Officer
Mr. Max Rosett
Chief Financial Officer
Mr. Isaac Barchas, J.D.
Lead Independent Director
Lead Independent Director
Dr. Robert (Bob) Lechleider, M.D.
Dr. Robert (Bob) Lechleider, M.D.
Chief Medical Officer